Integrin Inhibitor

Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).

BI-1950 is a lymphocyte function-associated antigen 1 (LFA-1) inhibitor. BI-1950 regulates immune system function through interaction with LFA-1. BI-1950 can be used in the research of inflammatory diseases.

AFP464 (NSC710464) is a prodrug of Aminoflavone (HY-132974) and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 is applicable to research related to breast cancer.

ATL 1102 (Avicursen) sodium is a novel second-generation antisense oligonucleotide to CD49d mRNA

Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina.

Anti-Fibulin-4 Antibody (5G11) reacts with the human fibulin-4. Anti-Fibulin-4 Antibody (5G11) does not show any crossreactivity with other family members. Fibulin-4 is an elastic-fibre-associated glycoprotein.

Crocatin B is found in P. crocatum Ruiz & Pav. Crocatin B exerts anti-inflammatory activity by inhibiting the expression of TNF-α and ICAM-1. Crocatin B has anti-tumor activity.

Anti-Mouse CD11b Antibody (5C6) is a CD11b blocking antibody. Anti-Mouse CD11b Antibody (5C6) can be used for in vitro inhibition of myelomonocytic cell adhesion and in vivo inhibition of inflammatory cell recruitment. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption.

IP/EP4 receptor agonist-1 is a PGI₂ analog and also an IP/EP4 receptor agonist. IP/EP4 receptor agonist-1 inhibits PAR-mediated integrin α_IIbβ₃ activation, P-selectin exposure, platelet aggregation and thrombus formation. IP/EP4 receptor agonist-1 can be used in research related to pulmonary hypertension.

Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ∼5 and ∼6.5 μM.

GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM).

Anti-Integrin α9 Antibody is an anti-Integrin α9 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.

Anti-Mouse CD18 Antibody (C71/16) reacts with an epitope on mouse CD18. CD18 is the Integrin β2 chain. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

PDI-IN-4 is a highly selective inhibitor of human PDI (IC₅₀=0.48 μM) with no significant cytotoxicity. PDI-IN-4 binds to PDI in a reversible manner, not only forming a covalent bond with the Cys400 residue but also engaging in hydrophobic interactions with other residues. By inhibiting the activation of GPIIb/IIIa, PDI-IN-4 effectively blocks platelet aggregation and thrombus formation. PDI-IN-4 can serve as an important tool reagent for thrombosis-related research.

SP-8008 is a selective shear stress-induced platelet aggregation (SIPA) inhibitor with an IC₅₀ of 1.44 μM. SP-8008 effectively interferes von Willebrand factor (vWF) and platelet glycoprotein (GP) Ib interaction. SP-8008 exerts its antithrombotic effect by selectively inhibiting shear stress-induced platelet aggregation.

(S)-Deethyl-emvistegrast is the S-enantiomer of Deethyl-emvistegrast (HY-186079). Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. It acts as the hydrolysis product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways and can be used in research related to inflammatory bowel diseases (Crohn's disease and ulcerative colitis).

GSK3335103 is an orally active non-peptidic αvβ6 integrin inhibitor with a pIC₅₀ of 8 and a pK_i of 9.96. GSK3335103 blocks αvβ6 integrin-mediated cell adhesion and TGF-β1 activation, induces integrin internalization, recycling and lysosomal degradation, attenuates TGFβ signaling and reduces collagen deposition. GSK3335103 decreases the level of pSmad2 in BAL cells and collagen deposition in lung tissues in a mouse model of pulmonary fibrosis. GSK3335103 can be used in research related to pulmonary fibrosis.

MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research.